Axovant Gene Therapies Ltd. is changing its name to Sio Gene Therapies Inc., effective Nov. 13.

The New York-based developer of gene therapies will use new ticker symbol SIOX on the Nasdaq.

The new identity reflects the company's "scientific vision to develop disease-modifying and curative genetic medicines," said Axovant CEO Pavan Cheruvu.

The company develops medicines for debilitating neurodegenerative diseases. Its gene therapies AXO-AAV-GM2 and AXO-AAV-GM1 recently received rare pediatric disease designations in the U.S. for the treatment of GM2 gangliosidosis and GM1 gangliosidosis, respectively.